Blog > Archive by tag 'FDA approval'

Tag: FDA approval

 

The TFN Complete Guide to Biotech Penny Stocks

Published on July 24, 2009

In the course of our research to find the best biotech penny stocks, we compiled a list of all viable companies trading for less than $5 on U.S. exchanges. We appreciate that many of our TFN readers like to do their own analysis and hope this will prove a useful tool…
by The TFN Team
The following [...]

Posted by Laura Cadden · Filed Under Featuring..., Investment Research, Investment Strategies, Politics, US Stocks and Markets | 5 Comments 

Is no news good news at Dyax Corp. (DYAX)?

Published on March 26, 2009

There’s been no news at all on Dyax Corp’s (NASDAQ:DYAX) approval of DX-88 through the FDA. What to do now?
***Breaking news: Expect a Dyax press release later today!
by J. Christoph Amberger
Baltimore—TFN: Tuesday afternoon, I posted an article called “Dyax Corp. (DYAX) could soar on FDA approval for DX-88 HAE drug” at our TFN news portal. [...]

Posted by J. Christoph Amberger · Filed Under US Stocks and Markets | 2 Comments 

Dyax Corp. (DYAX) could soar on FDA approval for DX-88 HAE drug

Published on March 24, 2009

Dyax Corp. (NASDAQ:DYAX) is looking for FDA approval on Wednesday.
by J. Christoph Amberger
Baltimore—TFN: In early February, the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Advisory Committee voted in favor of approving the drug DX-88 for the treatment of acute attacks of hereditary angioedema (HAE).
The majority was razor-thin: There were 6 yes votes, 5 no [...]

Posted by J. Christoph Amberger · Filed Under US Stocks and Markets | Leave a Comment 

Best Options Play: Leverage FDA approval in this $2.55 stock into potential 300% options gains

Published on March 19, 2009

A tiny medical microcap stock expects FDA approval on Monday. Using options to leverage to expected upward momentum could result in 300% gains!
by J. Christoph Amberger
Baltimore—TFN: “The major indexes may be well into negative territory,” writes TFN’s options oracle Andrew Snyder in his internal brief: “But the action won’t bring a frown to the face [...]

Posted by J. Christoph Amberger · Filed Under Options | Leave a Comment 

Best Stock to Buy: 6 Days to “Judgment Day” for this $2.50 Microcap

Published on March 18, 2009

On March 23, 2009, government approval for this Massachusetts microcap’s drug could trigger a volume spike that carries the stock to triple-digit gains.
by J. Christoph Amberger
Baltimore—TFN: By March 23, 2009, behind closed doors, one of the government’s most notorious “Judgment Day Tribunals” will decide the fate of a $2.50 microcap. Our analysts believe that its [...]

Posted by J. Christoph Amberger · Filed Under Investment Strategies | Leave a Comment